McKinsey January 9, 2023
Recent developments have complicated the outlook for industry profit pools.
When we last looked at the trajectory of the US healthcare industry in our July 2022 article, “The future of US healthcare: What’s next for the industry post-COVID-19?,” we had emerging concerns about what persistent inflation could cause.1 It is now clear that inflation is not transitory and that the economic outlook has meaningfully darkened.2 These economic troubles, combined with a healthcare-worker shortage and endemic COVID-19, are clouding the industry outlook. Below, we update how these changes could affect payers, providers, healthcare services and technology (HST), and pharmacy services.
Commercial and Medicare Advantage segments, physician offices, HST and specialty pharmacy segments may grow most quickly.
Based on updated...